ArticleAntimicrobial stewardship & healthcare epidemiology : ASHE2023
Outcomes of high-dose oral beta-lactam definitive therapy compared to fluoroquinolone or trimethoprim-sulfamethoxazole oral therapy for bacteremia secondary to a urinary tract infection.
Article in Antimicrobial stewardship & healthcare epidemiology : ASHE, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Cefdinir Versus Cephalexin for the Treatment of Uncomplicated Urinary Tract Infections.Open forum infectious diseases · 2025Trial
- Urinary tract infections in children.Nature reviews. Urology · 2026Review
- Clinical outcomes with oral cephalosporins as definitive treatment of Enterobacterales bacteremia from a urinary source based on cefazolin minimum inhibitory concentration.Antimicrobial agents and chemotherapy · 2026Article
- Assessment of treatment outcomes in patients receiving high- versus low-dose sulfamethoxazole-trimethoprim for oral stepdown therapy in gram-negative bacteremia: a multi-center, retrospective cohort study.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Safety and efficacy of early oral switch in Enterobacterales bacteremia: a systematic review and meta-analysis.Journal of Yeungnam medical science · 2026Article
- Profile of antimicrobial resistance of uropathogens in urinary tract infections: An analysis of 1117 hospitalized patients in Brazil.IJID regions · 2025Article
- Susceptibility reporting and antibiotic prescribing for UTIs in the inpatient setting: a nudge toward improved stewardship.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Rise of the beta-lactams: a retrospective, comparative cohort of oral beta-lactam antibiotics as step-down therapy for hospitalized adults with acute pyelonephritis.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Compare outcomes of patients receiving high-dose oral beta-lactam versus standard oral therapy for Enterobacterales bacteremia from a urinary tract infection (UTI). Design: Retrospective, multicenter, observational cohort. Setting: Three Michigan community teaching hospitals. Patients: Adult patients admitted between February 1, 2020, and October 1, 2022, with gram-negative bacteremia from a urinary source were evaluated. Patients receiving active empiric intravenous (IV) antibiotics and transitioned to appropriately dosed oral cephalexin, amoxicillin, fluoroquinolone (FQ), or trimethoprim/sulfamethoxazole (TMP/SMX) were included. Patients receiving less than 72 hours of oral therapy, diagnosed with renal abscess, lobar nephronia, or expired during admission were excluded. Methods: Standard oral therapy was defined as FQ or TMP/SMX. The primary outcome compared the composite of recurrent bacteremia or mortality within 30 days of therapy between groups. Secondary outcomes compared recurrent UTI, emergency department or hospital readmission, and Results: 194 patients were included (beta-lactam, Conclusion: High-dose oral beta-lactams were as safe and effective as oral FQ or TMP/SMX for the treatment of bacteremia from a urinary source. Most patients received 8-10 days of therapy in both groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.